Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15129388 | 0.89 | PTGS2 (0.44) | PTGS2CSF1RGAAALDH1A1CFTR | |
| SCHEMBL22557782 | 0.88 | KDM4E (0.46) | PTGS2CSF1RGAAALDH1A1CFTR | |
| SCHEMBL15129543 | 0.87 | PTGS2 (0.43) | PTGS2CSF1RGAAALDH1A1CFTR | |
| SCHEMBL5989774 | 0.86 | CYP2C9 (0.47) | PTGS2CSF1RGAAALDH1A1CFTR | |
| SCHEMBL3867085 | 0.86 | FTO (0.47) | PTGS2MAPTMEN1HPGDKMT2A | |
| SCHEMBL1039157 | 0.84 | LMNA (0.46) | PTGS2CSF1RALDH1A1MAPK14MAPT | |
| SCHEMBL4545983 | 0.82 | MAPT (0.49) | GAAALDH1A1CFTRHSD17B10ABL1 | |
| SCHEMBL3426662 | 0.81 | PTGS2 (0.46) | PTGS2CSF1RALDH1A1ALOX5MAPK14 | |
| SCHEMBL14428417 | 0.81 | PTGS2 (0.46) | PTGS2CSF1RALOX5MAPK14MAPT | |
| SCHEMBL19367457 | 0.81 | PTGS2 (0.46) | PTGS2CSF1RALDH1A1ALOX5MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3000810-B1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | ARRAY BIOPHARMA INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-1663210-B1 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-3000810-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | Array Biopharma, Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2275102-B1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8513293-B2 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal | ARRAY BIOPHARMA INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2130536-B1 | N3 alkylated benzimidazole derivatives as mek inhibitors | ARRAY BIOPHARMA INC (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2130537-B1 | N3 alkylated benzimidazole derivatives as mek inhibitors | ARRAY BIOPHARMA INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120277277-A1 | Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal | ARRAY BIOPHARMA INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8193229-B2 | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193231-B2 | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1663210-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1482932-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1482932-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040116710-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277277-A1 | Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal | PCNA, MKI67, HRAS | PTGS2 3103/4885CSF1R 3508/4885GAA 454/4885 |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CDK2 | PTGS2 1278/4885CSF1R 1547/4885GAA 3150/4885 |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | BRAF, CCNI, NRAS | PTGS2 2122/4885CSF1R 1543/4885GAA 3646/4885 |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | PTGS2 2139/4885CSF1R 1352/4885GAA 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.